A Novel High-Content Screening-Based Method for Anti-Trypanosoma cruzi Drug Discovery Using Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes

Chagas disease is caused by Trypanosoma cruzi infection and remains a relevant cause of chronic heart failure in Latin America. The pharmacological arsenal for Chagas disease is limited, and the available anti-T. cruzi drugs are not effective when administered during the chronic phase. Cardiomyocyte...

Full description

Bibliographic Details
Main Authors: Diogo Crispim Nascimento Portella, Erik Aranha Rossi, Bruno Diaz Paredes, Tanira Matutino Bastos, Cássio Santana Meira, Carolina Vasques Kymie Nonaka, Daniela Nascimento Silva, Alex Improta-Caria, Diogo Rodrigo Magalhaes Moreira, Ana Cristina Lima Leite, Gevanio Bezerra de Oliveira Filho, José Maria Barbosa Filho, Ricardo Ribeiro dos Santos, Milena Botelho Pereira Soares, Bruno Solano de Freita Souza
Format: Article
Language:English
Published: Hindawi Limited 2021-01-01
Series:Stem Cells International
Online Access:http://dx.doi.org/10.1155/2021/2642807
id doaj-9fae47b067404108b9d3c40fddce80ac
record_format Article
spelling doaj-9fae47b067404108b9d3c40fddce80ac2021-08-23T01:32:10ZengHindawi LimitedStem Cells International1687-96782021-01-01202110.1155/2021/2642807A Novel High-Content Screening-Based Method for Anti-Trypanosoma cruzi Drug Discovery Using Human-Induced Pluripotent Stem Cell-Derived CardiomyocytesDiogo Crispim Nascimento Portella0Erik Aranha Rossi1Bruno Diaz Paredes2Tanira Matutino Bastos3Cássio Santana Meira4Carolina Vasques Kymie Nonaka5Daniela Nascimento Silva6Alex Improta-Caria7Diogo Rodrigo Magalhaes Moreira8Ana Cristina Lima Leite9Gevanio Bezerra de Oliveira Filho10José Maria Barbosa Filho11Ricardo Ribeiro dos Santos12Milena Botelho Pereira Soares13Bruno Solano de Freita Souza14Gonçalo Moniz InstituteGonçalo Moniz InstituteD’Or Institute for Research and Education (IDOR)Gonçalo Moniz InstituteGonçalo Moniz InstituteD’Or Institute for Research and Education (IDOR)Gonçalo Moniz InstitutePost-Graduate Program in Medicine and HealthGonçalo Moniz InstituteDepartment of Pharmaceutical SciencesDepartment of Pharmaceutical SciencesFederal University of ParaibaGonçalo Moniz InstituteGonçalo Moniz InstituteGonçalo Moniz InstituteChagas disease is caused by Trypanosoma cruzi infection and remains a relevant cause of chronic heart failure in Latin America. The pharmacological arsenal for Chagas disease is limited, and the available anti-T. cruzi drugs are not effective when administered during the chronic phase. Cardiomyocytes derived from human-induced pluripotent stem cells (hiPSC-CMs) have the potential to accelerate the process of drug discovery for Chagas disease, through predictive preclinical assays in target human cells. Here, we aimed to establish a novel high-content screening- (HCS-) based method using hiPSC-CMs to simultaneously evaluate anti-T. cruzi activity and cardiotoxicity of chemical compounds. To provide proof-of-concept data, the reference drug benznidazole and three compounds with known anti-T. cruzi activity (a betulinic acid derivative named BA5 and two thiazolidinone compounds named GT5A and GT5B) were evaluated in the assay. hiPSC-CMs were infected with T. cruzi and incubated for 48 h with serial dilutions of the compounds for determination of EC50 and CC50 values. Automated multiparametric analyses were performed using an automated high-content imaging system. Sublethal toxicity measurements were evaluated through morphological measurements related to the integrity of the cytoskeleton by phalloidin staining, nuclear score by Hoechst 33342 staining, mitochondria score following MitoTracker staining, and quantification of NT-pro-BNP, a peptide released upon mechanical myocardial stress. The compounds showed EC50 values for anti-T. cruzi activity similar to those previously described for other cell types, and GT5B showed a pronounced trypanocidal activity in hiPSC-CMs. Sublethal changes in cytoskeletal and nucleus scores correlated with NT-pro-BNP levels in the culture supernatant. Mitochondrial score changes were associated with increased cytotoxicity. The assay was feasible and allowed rapid assessment of anti-T. cruzi action of the compounds, in addition to cardiotoxicity parameters. The utilization of hiPSC-CMs in the drug development workflow for Chagas disease may help in the identification of novel compounds.http://dx.doi.org/10.1155/2021/2642807
collection DOAJ
language English
format Article
sources DOAJ
author Diogo Crispim Nascimento Portella
Erik Aranha Rossi
Bruno Diaz Paredes
Tanira Matutino Bastos
Cássio Santana Meira
Carolina Vasques Kymie Nonaka
Daniela Nascimento Silva
Alex Improta-Caria
Diogo Rodrigo Magalhaes Moreira
Ana Cristina Lima Leite
Gevanio Bezerra de Oliveira Filho
José Maria Barbosa Filho
Ricardo Ribeiro dos Santos
Milena Botelho Pereira Soares
Bruno Solano de Freita Souza
spellingShingle Diogo Crispim Nascimento Portella
Erik Aranha Rossi
Bruno Diaz Paredes
Tanira Matutino Bastos
Cássio Santana Meira
Carolina Vasques Kymie Nonaka
Daniela Nascimento Silva
Alex Improta-Caria
Diogo Rodrigo Magalhaes Moreira
Ana Cristina Lima Leite
Gevanio Bezerra de Oliveira Filho
José Maria Barbosa Filho
Ricardo Ribeiro dos Santos
Milena Botelho Pereira Soares
Bruno Solano de Freita Souza
A Novel High-Content Screening-Based Method for Anti-Trypanosoma cruzi Drug Discovery Using Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes
Stem Cells International
author_facet Diogo Crispim Nascimento Portella
Erik Aranha Rossi
Bruno Diaz Paredes
Tanira Matutino Bastos
Cássio Santana Meira
Carolina Vasques Kymie Nonaka
Daniela Nascimento Silva
Alex Improta-Caria
Diogo Rodrigo Magalhaes Moreira
Ana Cristina Lima Leite
Gevanio Bezerra de Oliveira Filho
José Maria Barbosa Filho
Ricardo Ribeiro dos Santos
Milena Botelho Pereira Soares
Bruno Solano de Freita Souza
author_sort Diogo Crispim Nascimento Portella
title A Novel High-Content Screening-Based Method for Anti-Trypanosoma cruzi Drug Discovery Using Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes
title_short A Novel High-Content Screening-Based Method for Anti-Trypanosoma cruzi Drug Discovery Using Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes
title_full A Novel High-Content Screening-Based Method for Anti-Trypanosoma cruzi Drug Discovery Using Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes
title_fullStr A Novel High-Content Screening-Based Method for Anti-Trypanosoma cruzi Drug Discovery Using Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes
title_full_unstemmed A Novel High-Content Screening-Based Method for Anti-Trypanosoma cruzi Drug Discovery Using Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes
title_sort novel high-content screening-based method for anti-trypanosoma cruzi drug discovery using human-induced pluripotent stem cell-derived cardiomyocytes
publisher Hindawi Limited
series Stem Cells International
issn 1687-9678
publishDate 2021-01-01
description Chagas disease is caused by Trypanosoma cruzi infection and remains a relevant cause of chronic heart failure in Latin America. The pharmacological arsenal for Chagas disease is limited, and the available anti-T. cruzi drugs are not effective when administered during the chronic phase. Cardiomyocytes derived from human-induced pluripotent stem cells (hiPSC-CMs) have the potential to accelerate the process of drug discovery for Chagas disease, through predictive preclinical assays in target human cells. Here, we aimed to establish a novel high-content screening- (HCS-) based method using hiPSC-CMs to simultaneously evaluate anti-T. cruzi activity and cardiotoxicity of chemical compounds. To provide proof-of-concept data, the reference drug benznidazole and three compounds with known anti-T. cruzi activity (a betulinic acid derivative named BA5 and two thiazolidinone compounds named GT5A and GT5B) were evaluated in the assay. hiPSC-CMs were infected with T. cruzi and incubated for 48 h with serial dilutions of the compounds for determination of EC50 and CC50 values. Automated multiparametric analyses were performed using an automated high-content imaging system. Sublethal toxicity measurements were evaluated through morphological measurements related to the integrity of the cytoskeleton by phalloidin staining, nuclear score by Hoechst 33342 staining, mitochondria score following MitoTracker staining, and quantification of NT-pro-BNP, a peptide released upon mechanical myocardial stress. The compounds showed EC50 values for anti-T. cruzi activity similar to those previously described for other cell types, and GT5B showed a pronounced trypanocidal activity in hiPSC-CMs. Sublethal changes in cytoskeletal and nucleus scores correlated with NT-pro-BNP levels in the culture supernatant. Mitochondrial score changes were associated with increased cytotoxicity. The assay was feasible and allowed rapid assessment of anti-T. cruzi action of the compounds, in addition to cardiotoxicity parameters. The utilization of hiPSC-CMs in the drug development workflow for Chagas disease may help in the identification of novel compounds.
url http://dx.doi.org/10.1155/2021/2642807
work_keys_str_mv AT diogocrispimnascimentoportella anovelhighcontentscreeningbasedmethodforantitrypanosomacruzidrugdiscoveryusinghumaninducedpluripotentstemcellderivedcardiomyocytes
AT erikaranharossi anovelhighcontentscreeningbasedmethodforantitrypanosomacruzidrugdiscoveryusinghumaninducedpluripotentstemcellderivedcardiomyocytes
AT brunodiazparedes anovelhighcontentscreeningbasedmethodforantitrypanosomacruzidrugdiscoveryusinghumaninducedpluripotentstemcellderivedcardiomyocytes
AT taniramatutinobastos anovelhighcontentscreeningbasedmethodforantitrypanosomacruzidrugdiscoveryusinghumaninducedpluripotentstemcellderivedcardiomyocytes
AT cassiosantanameira anovelhighcontentscreeningbasedmethodforantitrypanosomacruzidrugdiscoveryusinghumaninducedpluripotentstemcellderivedcardiomyocytes
AT carolinavasqueskymienonaka anovelhighcontentscreeningbasedmethodforantitrypanosomacruzidrugdiscoveryusinghumaninducedpluripotentstemcellderivedcardiomyocytes
AT danielanascimentosilva anovelhighcontentscreeningbasedmethodforantitrypanosomacruzidrugdiscoveryusinghumaninducedpluripotentstemcellderivedcardiomyocytes
AT aleximprotacaria anovelhighcontentscreeningbasedmethodforantitrypanosomacruzidrugdiscoveryusinghumaninducedpluripotentstemcellderivedcardiomyocytes
AT diogorodrigomagalhaesmoreira anovelhighcontentscreeningbasedmethodforantitrypanosomacruzidrugdiscoveryusinghumaninducedpluripotentstemcellderivedcardiomyocytes
AT anacristinalimaleite anovelhighcontentscreeningbasedmethodforantitrypanosomacruzidrugdiscoveryusinghumaninducedpluripotentstemcellderivedcardiomyocytes
AT gevaniobezerradeoliveirafilho anovelhighcontentscreeningbasedmethodforantitrypanosomacruzidrugdiscoveryusinghumaninducedpluripotentstemcellderivedcardiomyocytes
AT josemariabarbosafilho anovelhighcontentscreeningbasedmethodforantitrypanosomacruzidrugdiscoveryusinghumaninducedpluripotentstemcellderivedcardiomyocytes
AT ricardoribeirodossantos anovelhighcontentscreeningbasedmethodforantitrypanosomacruzidrugdiscoveryusinghumaninducedpluripotentstemcellderivedcardiomyocytes
AT milenabotelhopereirasoares anovelhighcontentscreeningbasedmethodforantitrypanosomacruzidrugdiscoveryusinghumaninducedpluripotentstemcellderivedcardiomyocytes
AT brunosolanodefreitasouza anovelhighcontentscreeningbasedmethodforantitrypanosomacruzidrugdiscoveryusinghumaninducedpluripotentstemcellderivedcardiomyocytes
AT diogocrispimnascimentoportella novelhighcontentscreeningbasedmethodforantitrypanosomacruzidrugdiscoveryusinghumaninducedpluripotentstemcellderivedcardiomyocytes
AT erikaranharossi novelhighcontentscreeningbasedmethodforantitrypanosomacruzidrugdiscoveryusinghumaninducedpluripotentstemcellderivedcardiomyocytes
AT brunodiazparedes novelhighcontentscreeningbasedmethodforantitrypanosomacruzidrugdiscoveryusinghumaninducedpluripotentstemcellderivedcardiomyocytes
AT taniramatutinobastos novelhighcontentscreeningbasedmethodforantitrypanosomacruzidrugdiscoveryusinghumaninducedpluripotentstemcellderivedcardiomyocytes
AT cassiosantanameira novelhighcontentscreeningbasedmethodforantitrypanosomacruzidrugdiscoveryusinghumaninducedpluripotentstemcellderivedcardiomyocytes
AT carolinavasqueskymienonaka novelhighcontentscreeningbasedmethodforantitrypanosomacruzidrugdiscoveryusinghumaninducedpluripotentstemcellderivedcardiomyocytes
AT danielanascimentosilva novelhighcontentscreeningbasedmethodforantitrypanosomacruzidrugdiscoveryusinghumaninducedpluripotentstemcellderivedcardiomyocytes
AT aleximprotacaria novelhighcontentscreeningbasedmethodforantitrypanosomacruzidrugdiscoveryusinghumaninducedpluripotentstemcellderivedcardiomyocytes
AT diogorodrigomagalhaesmoreira novelhighcontentscreeningbasedmethodforantitrypanosomacruzidrugdiscoveryusinghumaninducedpluripotentstemcellderivedcardiomyocytes
AT anacristinalimaleite novelhighcontentscreeningbasedmethodforantitrypanosomacruzidrugdiscoveryusinghumaninducedpluripotentstemcellderivedcardiomyocytes
AT gevaniobezerradeoliveirafilho novelhighcontentscreeningbasedmethodforantitrypanosomacruzidrugdiscoveryusinghumaninducedpluripotentstemcellderivedcardiomyocytes
AT josemariabarbosafilho novelhighcontentscreeningbasedmethodforantitrypanosomacruzidrugdiscoveryusinghumaninducedpluripotentstemcellderivedcardiomyocytes
AT ricardoribeirodossantos novelhighcontentscreeningbasedmethodforantitrypanosomacruzidrugdiscoveryusinghumaninducedpluripotentstemcellderivedcardiomyocytes
AT milenabotelhopereirasoares novelhighcontentscreeningbasedmethodforantitrypanosomacruzidrugdiscoveryusinghumaninducedpluripotentstemcellderivedcardiomyocytes
AT brunosolanodefreitasouza novelhighcontentscreeningbasedmethodforantitrypanosomacruzidrugdiscoveryusinghumaninducedpluripotentstemcellderivedcardiomyocytes
_version_ 1721199041184792576